EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An orthotopic syngeneic mouse model of bortezomib‐resistant multiple myeloma

Manjun Li iD, Melissa K Bennett iD, John Toubia iD, Victoria S Pope iD, Melinda N Tea iD, Sarah Tamang, Michael S Samuel iD, Paul H Anderson iD, Briony L Gliddon iD, Jason A Powell iD, Stuart M Pitson iD

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19240 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Manjun Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fay Fuller Foundation, National Health and Medical Research Council, Royal Adelaide Hospital Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While bortezomib has significant benefits in multiple myeloma (MM) therapy, the disease remains incurable due to the invariable development of bortezomib resistance. This emphasises the need for advanced models for preclinical evaluation of new therapeutic approaches for bortezomib‐resistant MM. Here, we describe the development of an orthotopic syngeneic bortezomib‐resistant MM mouse model based on the most well‐characterised syngeneic MM mouse model derived from spontaneous MM‐forming C57BL/KaLwRij mice. Using bortezomib‐resistant 5TGM1 cells, we report and characterise a robust syngeneic mouse model of bortezomib‐resistant MM that is well suited to the evaluation of new therapeutic approaches for proteasome inhibitor‐resistant MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic AgentsAnimalsMiceBortezomibMice, Inbred C57BLProteasome InhibitorsCell Line, TumorDrug Resistance, Neoplasm

Stichwörter der Autor:innen

KaLwRij micebortezomiblinsitinibmouse modelmyelomaresistance

Substanzen

BortezomibProteasome InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, South Australia, Australia.
  • Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
  • Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
  • School of Biological Sciences, University of Adelaide, Adelaide, South Australia, Australia.

ORCID-Profile: Manjun Li, Melissa K Bennett, John Toubia, Victoria S Pope, Melinda N Tea, Michael S Samuel, Paul H Anderson, Briony L Gliddon, Jason A Powell, Stuart M Pitson

Förderung

  • Fay Fuller Foundation
  • National Health and Medical Research Council
  • Royal Adelaide Hospital Research Fund
  • Australian Government Research Training Program Scholarship

Zitieren

APA

Li, M., Bennett, M. K., Toubia, J., Pope, V. S., Tea, M. N., Tamang, S., Samuel, M. S., Anderson, P. H., Gliddon, B. L., Powell, J. A., & Pitson, S. M. (2024). An orthotopic syngeneic mouse model of bortezomib‐resistant multiple myeloma. British Journal of Haematology. https://doi.org/10.1111/bjh.19240

Vancouver

Li M, Bennett MK, Toubia J, Pope VS, Tea MN, Tamang S, et al. An orthotopic syngeneic mouse model of bortezomib‐resistant multiple myeloma. British Journal of Haematology. 2024. doi:10.1111/bjh.19240

BibTeX
@article{Li2024,
  author = {Li, Manjun and Bennett, Melissa K and Toubia, John and Pope, Victoria S and Tea, Melinda N and Tamang, Sarah and Samuel, Michael S and Anderson, Paul H and Gliddon, Briony L and Powell, Jason A and Pitson, Stuart M},
  title = {An orthotopic syngeneic mouse model of bortezomib‐resistant multiple myeloma},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19240}
}
Kostenlos starten →